posted on 2017-09-13, 09:21authored byNiamh O'Halloran, Donald Courtney, Michael J. Kerin, Aoife J. Lowery
Adipose-derived stem cells (ADSCs) are rapidly becoming the gold standard cell source for tissue engineering strategies and hold great potential for novel breast reconstruction strategies. However, their use in patients with breast cancer is controversial and their
oncological safety, particularly in relation to local disease recurrence, has been questioned. In vitro, in vivo, and clinical studies using ADSCs report conflicting data on their suitability for adipose tissue regeneration in patients with cancer. This review aims to provide an overview of the potential role for ADSCs in breast reconstruction and to examine the evidence relating to the oncologic safety of their use in patients with breast
cancer.
History
Publication
Breast Cancer: Basic and Clinical Research;11, pp. 1-18